Vir Biotechnology Inc (NASDAQ:VIR) shares fell 15% in premarket trade Friday following the company's announcement of a $150 million public stock offering priced at $10 per share.
A promising biotechnology company developed a new approach that might treat a rare disease — but its sole employee didn’t do ...
Vir Biotechnology has exclusive rights to the universal PRO-XTEN ® masking platform for oncology and infectious disease.
Vir Biotechnology has exclusive rights to the universal PRO-XTEN ® masking platform for oncology and infectious disease.
Vir Biotechnology, Inc. (NASDAQ:VIR) stock fell in Friday’s premarket trading after the clinical-stage biopharmaceutical company priced a $150 million public stock offering at $10 per share, raising ...
Vir Biotechnology (NASDAQ:VIR) said its combination treatment for chronic hepatitis delta met the primary and key secondary ...
Overview: Quantum computing, AI, and advanced semiconductors could transform data processing and scientific research.Robotics ...
Huron Daily Tribune on MSN
PDS Biotechnology: Q3 earnings snapshot
EAST PRINCETON, N.J. (AP) — EAST PRINCETON, N.J. (AP) — PDS Biotechnology Corporation (PDSB) on Friday reported a loss of ...
Agricultural biotechnology once found itself in opposition to environmental science. Now it could reduce the impact of food ...
Vir Biotechnology remains a Buy after flawless Phase 3 ECLIPSE 1 results and a major new Gilead partnership. Read more on VIR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results